Scientists have slowed the progression of Huntington’s disease for the first time with a “groundbreaking” new treatment.
In an update from uniQure, they report that their experimental gene therapy, AMT-130, has the potential to slow Huntington’s ...
A new study published in Brain Sciences provides evidence that dopamine promotes movement by directly altering the excitability of key neurons in the brain’s motor circuitry. The research identifies a ...
Scientists have slowed the progression of Huntington’s disease for the first time with a “groundbreaking” new treatment.
A global clinical trial for a new Huntington's disease treatment has posted positive results today, announced by trial sponsor uniQure and UCL ...
After 36 months, patients treated with high dose AMT-130 saw a 75% slowing of disease progression vs the external control.
Discover Alector's latest breakthroughs in neurodegenerative disease therapies, including updates on Alzheimer's and Parkinson's programs.